|
With a triple pandemic of COVID, flu, and RSV hitting the US hard this winter and resulting in an explosion of cases, business executives need to take the lead on promoting the newly-updated, Omicron-specific boosters. Doing so will help reduce the number of sick days taken by their workers, minimize COVID outbreaks and superspreader events in their companies, reduce employee fears about returning to the office, and position executives as trustworthy participants in stakeholder capitalism.
Research shows that the new boosters from Pfizer and Moderna, which are bivalent - meaning they target both Omicron and the original COVID strain - are very safe, similar to current vaccines. They are also more effective than previous vaccines against the Omicron variants, which are prevalent in the US and elsewhere around the globe.
| 
